NOVO NORDISK INC.
PLAINSBORO, NJ

Every year, Novo Nordisk publishes a single, integrated report on our performance. Most companies publish such reports, but many publish a separate environmental report alongside their annual financial report. Since 2004, Novo Nordisk has published one integrated report to reflect the  Novo Nordisk Triple Bottom Line business principle Not only does integrated reporting reflect Novo Nordisk’s objective to ‘conduct our activities in a financially, environmentally and socially responsible way’, but by reporting in one inclusive document we provide a more comprehensive overview of the company’s performance, progress, positions and strategic initiatives. and consists of a set of content elements and guiding principles intended to improve the quality of information available to providers of financial capital. The guiding principles for integrated reporting are: strategic focus and future orientation, connectivity of information, stakeholder relationships, materiality, conciseness, reliability and completeness, and consistency and comparability. See how Novo Nordisk applies the <IR> Framework and read our most recent Novo Nordisk considers the use of animals to be essential for the discovery, development and production of pharmaceutical and medical products. Ethical considerations and animal welfare are given high priority and we support the principles of the 3Rs (Reduce, Refine and Replace) and are integrating these principles in all our process and procedures. We have formulated positions on issues of relevance to our business and our role as a global corporate citizen. Novo Nordisk sees the SDGs as an opportunity “There is a growing acknowledgement of the importance of the private sector in working with institutions, governments and others to solve problems – and Novo Nordisk is ready to forge new partnerships.” Lars Fruergaard Jørgensen, President and chief executive officer, Novo Nordisk The conclusion of the assessment is that we will have the most impact on Goal 3 on Health and Goal 12 on Responsible Consumption and Production. You can read more on what we currently do to maximise our positive impact and minimise our negative impact on our way of doing business We have built our business on the conviction that the formula for lasting success is to stay focused, think long-term and do business in a financially, socially and environmentally responsible way. That is why we manage our business in accordance with the Triple Bottom Line principle.  A passion for helping people The story of Novo Nordisk goes back more than 90 years Who we are Novo Nordisk is a global healthcare company with 95 years of innovation and leadership in diabetes care. This heritage has given us experience and capabilities that also enable us to help people defeat obesity, haemophilia, growth disorders and other serious chronic diseases. Headquartered in Denmark, Novo Nordisk employs approximately 42,100 people in 79 countries and markets its products in more than 170 countries.  Novo Nordisk websites Alvin is one of seven employees recruited through Project Opportunity – a unique employment programme that seeks to match existing job vacancies within the company’s Danish organisation with the unique talents and qualifications of people living with autism spectrum disorder (ASD). The brainchild of senior facilitator Liselotte Hyveled, whose own daughter lives with autism, the programme was initiated in 2013. It is run in collaboration with Denmark’s National Autism Institute, which acts as a recruitment consultant and provides ongoing advice and support to recruits – as well as Novo Nordisk. “This is a unique model and we were the first company in Denmark offering it,” Liselotte explains. “The number of people with autism is frightening – and the problem is global. Many of these people are well-functioning and highly intelligent, but the majority of them are not in employment.” For Liselotte – and for Novo Nordisk - the project has been an eye-opening experience, and a way to consider talent in a broader perspective. “At Novo Nordisk, we are really good at looking at processes and strategic fit. But we need people who can do other things – perhaps from quirkier angles than we are used to,” she explains. “After I started working at Novo Nordisk I became much more structured in my personal life – I’m much more organised now,” he says. “Moving out of my parent’s home was a huge change for me; it would have been much harder without the experience from Novo Nordisk.” Explore features and points of view from Novo Nordisk Novo Nordisk Chief science officer Mads Krogsgaard Thomsen reflects on the past, present and future of insulin in a tablet. President and chief executive officer of Novo Nordisk, Lars Fruergaard Jørgensen on why the definition of obesity is just the beginning of a broader, more significant discussion. We have set an ambitious target of converting all our global production sites to 100% renewable power by 2020. With millions displaced by war, business has a key role in helping refugees integrate, contribute and flourish in society. With a little help from our peers Can your peers help prevent type 2 diabetes? Henriette Curtz Jansen from Copenhagen municipality thinks so and shares how peer networks have been successful in Denmark. Simone, an employee of Novo Nordisk, reflects on her perpetual battles with type 2 diabetes, heart disease and stigmatisation. Who we are Novo Nordisk is a global healthcare company with 95 years of innovation and leadership in diabetes care. This heritage has given us experience and capabilities that also enable us to help people defeat obesity, haemophilia, growth disorders and other serious chronic diseases. Headquartered in Denmark, Novo Nordisk employs approximately 42,100 people in 79 countries and markets its products in more than 170 countries.  Novo Nordisk websites Who we are Novo Nordisk is a global healthcare company with 95 years of innovation and leadership in diabetes care. This heritage has given us experience and capabilities that also enable us to help people defeat obesity, haemophilia, growth disorders and other serious chronic diseases.